AutoSynVax (AGEN2107) / Agenus - LARVOL DELTA

Phase 1a Study to Evaluate Immunogenicity of ASV® (clinicaltrials.gov) - P1a; N=3; Completed; Sponsor: Agenus Inc.; Active, not recruiting ➔ Completed; Trial completion date: Sep 2021 ➔ Feb 2021

Clinical • Trial completion • Trial completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A phase 1 study of safety and tolerability of AutoSynVax™ vaccine in patients with advanced cancer. (SITC 2018) - P1; "Trial Registrationl NCT02992977 ; Background Agenus AutoSynVax™ (ASV™), AGEN2003, is an individualized, fully synthetic neoantigen vaccine comprised of computationally defined peptide immunogens complexed to recombinant heat shock protein (HSP) and administered with QS-21 Stimulon® adjuvant. In animal models and clinical trials, vaccines employing HSP-peptide complexes mixed with QS-21 elicit antigen-specific CD8+ and CD4+ T-cell responses. Methods After signing an informed"

Clinical • P1 data • Oncology

Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer (clinicaltrials.gov) - P1; N=3; Terminated; Sponsor: Agenus Inc.; N=20 ➔ 3; Trial completion date: Mar 2019 ➔ Dec 2019; Active, not recruiting ➔ Terminated; To enable development of an enhanced version of the vaccine.

Clinical • Enrollment change • Trial completion date • Trial termination